Related references
Note: Only part of the references are listed.Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
Amit Assa et al.
JOURNAL OF CROHNS & COLITIS (2013)
Durability of Infliximab Dose Intensification in Crohn's Disease
Kirk K. Lin et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
David S. Kotlyar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension
Jeffrey Hyams et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response
Maria Chaparro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
Primary EBV Infection Resulting in Lymphoproliferative Disease in a Teenager With Crohn Disease
Dominica Gidrewicz et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2011)
Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
Jeffrey S. Hyams et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data
E. I. Benchimol et al.
GUT (2009)
Durability of Infliximab in Crohn's Disease: A Single-Center Experience
Jason E. Gonzaga et al.
INFLAMMATORY BOWEL DISEASES (2009)
Long-term Outcome of Maintenance Infliximab Therapy in Children with Crohn's Disease
Jeffrey S. Hyoms et al.
INFLAMMATORY BOWEL DISEASES (2009)
W1244 Efficacy of a Third Anti-TNF Monoclonal Antibody in Crohn's Disease After Failure of Two Other Anti-TNF
Nicolas Mozziconacci et al.
GASTROENTEROLOGY (2008)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?
Joel R. Rosh et al.
INFLAMMATORY BOWEL DISEASES (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
Ann Corken Mackey et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
WJ Sandborn et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A statewide population-based study
S Kugathasan et al.
JOURNAL OF PEDIATRICS (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
